Last Updated: November 16, 2026

Investigational Drug Information for PF-06650833

« Back to Dashboard


What is the development status for investigational drug PF-06650833?

PF-06650833 is an investigational drug.

There have been 12 clinical trials for PF-06650833. The most recent clinical trial was a Phase 2 trial, which was initiated on December 2nd 2019.

The most common disease conditions in clinical trials are Arthritis, Rheumatoid, Arthritis, and COVID-19. The leading clinical trial sponsors are Pfizer, Yale University, and Giovanni Franchin, M.D, Ph.D.

There are seventy-two US patents protecting this investigational drug and eighty-six international patents.

Recent Clinical Trials for PF-06650833
TitleSponsorPhase
A Study To Estimate The Effect of PF-06650833 On The Pharmacokinetics (PK) of Oral Contraceptive (OC)PfizerPhase 1
IRAK 4 Inhibitor (PF-06650833) in Hospitalized Patients With COVID-19 Pneumonia and Exuberant Inflammation.PfizerPhase 2
IRAK 4 Inhibitor (PF-06650833) in Hospitalized Patients With COVID-19 Pneumonia and Exuberant Inflammation.Giovanni Franchin, M.D, Ph.DPhase 2

See all PF-06650833 clinical trials

Clinical Trial Summary for PF-06650833

Top disease conditions for PF-06650833
Top clinical trial sponsors for PF-06650833

See all PF-06650833 clinical trials

US Patents for PF-06650833

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
PF-06650833 ⤷  Start Trial Bicyclic-fused heteroaryl or aryl compounds Pfizer Inc. (New York, NY) ⤷  Start Trial
PF-06650833 ⤷  Start Trial Bicyclic-fused heteroaryl or aryl compounds Pfizer Inc. (New York, NY) ⤷  Start Trial
PF-06650833 ⤷  Start Trial IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (Cambridge, MA) ⤷  Start Trial
PF-06650833 ⤷  Start Trial N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as CCR6 inhibitors Pfizer Corp SRL ⤷  Start Trial
PF-06650833 ⤷  Start Trial Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides Arvinas Inc , Arvinas Operations Inc ⤷  Start Trial
PF-06650833 ⤷  Start Trial IRAK degraders and uses thereof Kymera Therapeutics Inc ⤷  Start Trial
PF-06650833 ⤷  Start Trial IRAK degraders and uses thereof Kymera Therapeutics Inc ⤷  Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for PF-06650833

Drugname Country Document Number Estimated Expiration Related US Patent
PF-06650833 Argentina AR099955 2034-04-04 ⤷  Start Trial
PF-06650833 Australia AU2015242291 2034-04-04 ⤷  Start Trial
PF-06650833 Canada CA2944475 2034-04-04 ⤷  Start Trial
PF-06650833 Chile CL2016002524 2034-04-04 ⤷  Start Trial
PF-06650833 China CN106458912 2034-04-04 ⤷  Start Trial
PF-06650833 Costa Rica CR20160456 2034-04-04 ⤷  Start Trial
PF-06650833 Cuba CU20160149 2034-04-04 ⤷  Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

PF-06650833 Development Update and Market Projection

Last updated: September 7, 2026

PF-06650833 is an oral, selective interleukin-1 receptor-associated kinase 4, or IRAK4, inhibitor developed by Pfizer for inflammatory diseases, primarily rheumatoid arthritis. The candidate reached Phase 2 clinical testing but has not advanced to a pivotal Phase 3 program, regulatory filing, or commercial launch. Its current commercial value is therefore tied to licensing or redevelopment potential rather than product revenue.

The base-case market projection is zero near-term revenue. No FDA approval, Orange Book listing, U.S. generic competition, biosimilar exposure, or confirmed launch timetable has been identified for PF-06650833. A commercial recovery would require Pfizer or another sponsor to restart development, select a differentiated indication, and generate new Phase 2 or Phase 3 evidence.

What is PF-06650833 and how does it work?

PF-06650833 is a small-molecule IRAK4 inhibitor. IRAK4 is a signaling kinase involved in the MyD88-dependent pathway activated by several Toll-like receptors and interleukin-1 receptor family members. The pathway regulates inflammatory cytokine production and has been investigated as a target in rheumatoid arthritis, psoriasis, inflammatory bowel disease, systemic lupus erythematosus, and other immune-mediated conditions.

The candidate was designed to inhibit IRAK4 selectively rather than broadly suppressing Janus kinase, or JAK, signaling. That distinction was intended to provide anti-inflammatory activity while avoiding some of the class-wide safety and monitoring issues associated with JAK inhibitors.

Attribute PF-06650833
Sponsor Pfizer
Modality Small-molecule oral kinase inhibitor
Primary target IRAK4
Lead indication Rheumatoid arthritis
Development stage reached Phase 2
FDA approval None identified
Commercial launch None
Orange Book listing None
Current market revenue None
Principal commercial risk Development inactivity and competition from approved immunomodulators

Clinical testing evaluated PF-06650833 in adults with moderate-to-severe rheumatoid arthritis, including patients with inadequate response to conventional disease-modifying antirheumatic drugs. The public trial record indicates that the candidate progressed beyond first-in-human testing into controlled Phase 2 evaluation. [1]

What is the development status of PF-06650833?

PF-06650833 has not demonstrated visible advancement into Phase 3 development or a regulatory submission. The principal development signal is a completed or reported Phase 2 rheumatoid arthritis program. No approved label, biologics license application, new drug application, or marketing authorization has been associated with the compound.

Development timeline

Period Development event Commercial implication
Pre-2017 Pfizer conducts preclinical and early clinical work on IRAK4 inhibition Establishes mechanism and initial safety package
2017 onward Phase 2 rheumatoid arthritis studies begin or are registered Candidate enters proof-of-concept development
Phase 2 period Efficacy and safety are evaluated in patients with active rheumatoid arthritis Determines whether the program can justify pivotal trials
Post-Phase 2 No publicly visible Phase 3 program or regulatory filing Substantially reduces probability of near-term launch
Current public position No approved product or commercial sales Revenue forecast remains zero in the base case

The absence of a Phase 3 program is more important than the existence of positive Phase 2 data. In rheumatoid arthritis, a sponsor generally needs durable efficacy data, a sufficiently differentiated safety profile, and a commercially credible positioning strategy against established biologic and targeted synthetic DMARDs.

No recent public evidence indicates that Pfizer has prioritized PF-06650833 as a core immunology asset. That does not establish a legal abandonment of every patent or a formal termination of every development right. It does indicate that the candidate has no visible path to near-term commercialization.

What clinical evidence supports PF-06650833?

The clinical rationale for PF-06650833 is based on inhibiting innate immune signaling upstream of inflammatory cytokine production. The Phase 2 rheumatoid arthritis program was designed to assess changes in disease activity and responder rates over a relatively short treatment period.

The key commercial limitation is the lack of a publicly established late-stage efficacy and safety profile. A Phase 2 signal alone does not establish whether PF-06650833 can compete with:

  • Tumor necrosis factor inhibitors such as adalimumab and etanercept.
  • Interleukin-6 inhibitors such as tocilizumab and sarilumab.
  • T-cell costimulation modulators such as abatacept.
  • B-cell depletion therapy such as rituximab.
  • JAK inhibitors such as upadacitinib, tofacitinib, baricitinib, and deucravacitinib in relevant settings.

IRAK4 inhibition could offer a differentiated mechanism, but differentiation must translate into measurable advantages in remission rates, speed of response, steroid reduction, durability, safety, route of administration, or use in patients who fail existing therapies.

When would PF-06650833 lose exclusivity?

PF-06650833 does not have a commercial exclusivity date comparable to an approved drug because it has not reached FDA approval. Patent expiry cannot be treated as a market-entry date without an approved product, issued patent claims covering the marketed form, and enforceable regulatory rights.

Patent and exclusivity position

Rights category Public commercial position
Composition-of-matter patents Patent families may exist, but a complete enforceable claim chart is not established here
Formulation patents No marketed formulation or verified FDA-linked formulation patent
Method-of-use patents Rheumatoid arthritis and other inflammatory indications may be covered by patent filings, but no Orange Book-listed use patent exists
FDA new chemical entity exclusivity Not granted because no NDA approval has been identified
Orphan-drug exclusivity No identified orphan approval
Pediatric exclusivity None identified
Orange Book status No listing identified
Generic entry No ANDA-based entry pathway identified
Biosimilar entry Not applicable to this small molecule

PF-06650833 may be covered by unpublished, pending, expired, abandoned, or issued patent families in the United States and other jurisdictions. Patent ownership, term, terminal disclaimers, prosecution status, and claim scope require a family-level patent review. The absence of an Orange Book listing means that any patent protection would not currently create an FDA-listed barrier to generic approval.

What is the FDA regulatory status of PF-06650833?

PF-06650833 is not an FDA-approved drug. It does not appear as an approved product in Drugs@FDA or as a listed drug with Orange Book exclusivity. [2,3]

No public record identifies:

  • An approved NDA.
  • A tentative approval.
  • A reference listed drug designation.
  • A Paragraph IV certification.
  • An FDA-recognized patent dispute involving the compound.
  • A commercial label.
  • An approved indication or dosage regimen.

Because PF-06650833 has no approved reference product, generic applicants cannot currently use the conventional ANDA pathway to challenge an Orange Book patent listing for this compound.

Which companies are challenging PF-06650833?

No public Paragraph IV challenger or biosimilar competitor has been identified. The absence of challengers reflects the candidate's precommercial status, not confirmed freedom from competition.

The more relevant competitive threat comes from approved or late-stage immunology products. Rheumatoid arthritis physicians already have access to multiple biologic and oral targeted therapies. An IRAK4 inhibitor would need to displace established treatment sequences rather than enter an unserved market.

Competitive comparison

Product class Representative products Development or commercial advantage over PF-06650833
TNF inhibitors Humira, Enbrel, Remicade and biosimilars Large clinical history and broad reimbursement
IL-6 inhibitors Actemra, Kevzara Established mechanism and approved use
JAK inhibitors Rinvoq, Xeljanz, Olumiant Oral dosing and extensive commercial infrastructure
Costimulation modulation Orencia Established positioning in rheumatoid arthritis
B-cell therapy Rituxan and biosimilars Use in selected refractory populations
IRAK4 inhibition PF-06650833 Mechanistic differentiation but no approved product

PF-06650833 also faces competition from other IRAK4 programs. Zimlovisertib and additional IRAK4 inhibitors have been evaluated in inflammatory and autoimmune diseases by companies seeking to validate the mechanism. Competitive development in ulcerative colitis, Crohn's disease, hidradenitis suppurativa, lupus, and rheumatoid arthritis could reduce the value of PF-06650833 unless Pfizer retains a meaningful pharmacologic or patent advantage.

What formulations are protected by PF-06650833?

PF-06650833 was developed as an oral small molecule. No marketed dosage form exists, and no FDA-approved formulation patent has been identified.

The commercial formulation questions would include:

  • Immediate-release versus modified-release tablets.
  • Dose strength and titration requirements.
  • Food-effect management.
  • Stability and shelf-life.
  • Manufacturing yield and impurity controls.
  • Solid-state form and polymorph protection.
  • Salt, crystalline, or amorphous form claims.
  • Combination use with methotrexate or other DMARDs.

A formulation patent could extend protection beyond a basic composition-of-matter patent, but only if the formulation is clinically necessary, difficult to design around, and commercially relevant. There is no public evidence that PF-06650833 has a marketed formulation with independent regulatory value.

What patent litigation affects PF-06650833?

No material U.S. patent litigation involving PF-06650833 has been identified in the public regulatory record. No Orange Book patent litigation, ANDA litigation, or settlement agreement involving generic entry has been reported.

There is also no identified biosimilar litigation because PF-06650833 is a small molecule rather than a biologic. Any future litigation would more likely concern:

  1. Composition-of-matter claims.
  2. Salt, polymorph, or solid-form patents.
  3. Manufacturing-process patents.
  4. Method-of-treatment claims.
  5. Combination treatment with methotrexate or other DMARDs.
  6. Ownership or licensing rights if the asset is transferred.

How strong is the PF-06650833 patent estate?

The patent estate cannot be rated as commercially strong solely from Phase 2 development. The relevant issue is whether enforceable claims remain in major markets and whether those claims cover a viable commercial product through the expected launch period.

The estate would be stronger if it includes:

  • A valid composition-of-matter patent with a late expiration date.
  • Multiple non-overlapping claims to IRAK4 inhibition.
  • Independent solid-form or formulation claims.
  • Method-of-use claims covering rheumatoid arthritis and other high-value indications.
  • Manufacturing claims that are difficult to design around.
  • Patent term extension eligibility after approval.
  • Continuation applications preserving claim flexibility.

The estate would be weaker if the original compound patent is near expiry, if claims are narrow, if key applications were abandoned, or if competing IRAK4 compounds can avoid the protected structure. The lack of an approved product also means that any patent term extension analysis remains contingent on future regulatory approval.

What is the market projection for PF-06650833?

The base-case forecast is no commercial revenue through the near term because PF-06650833 lacks approval, a launch plan, and a visible Phase 3 program.

A scenario-based projection is more appropriate than a conventional product forecast:

Scenario Probability assessment Revenue outlook
No further development Base case Zero product revenue
Pfizer restarts development Low Revenue delayed by several years
Asset is licensed or acquired Low to moderate Depends on new indication and clinical reset
Successful Phase 3 in rheumatoid arthritis Low without new evidence Potential specialty immunology product
Successful indication expansion Low Could support a larger market, but requires new trials

Rheumatoid arthritis is a large pharmaceutical market, but size alone does not support a PF-06650833 forecast. The candidate would enter a crowded market with established biologics, oral targeted therapies, biosimilars, and payer step-editing requirements. A commercially viable launch would likely require a clear advantage in safety, oral convenience, efficacy after biologic failure, or a disease area where IRAK4 biology is more compelling.

A realistic development restart would require:

  • New sponsor commitment.
  • Updated toxicology and manufacturing review.
  • Confirmation of clinical exposure and dose selection.
  • A differentiated target indication.
  • A new Phase 2b or Phase 3 investment decision.
  • Updated patent and freedom-to-operate analysis.
  • Reimbursement evidence against entrenched competitors.

The asset's financial value is therefore option value. It is not a near-term revenue-generating product.

How does PF-06650833 compare with competing IRAK4 inhibitors?

PF-06650833 has the advantage of prior human clinical testing and a defined rheumatoid arthritis development history. That can reduce some early translational risk relative to preclinical IRAK4 programs.

Its disadvantages are more significant:

  • It has not reached Phase 3.
  • It has no approved indication.
  • It lacks established commercial differentiation.
  • It has no visible revenue base.
  • The rheumatoid arthritis market has strong incumbent competition.
  • Other IRAK4 programs may have stronger data in gastrointestinal or dermatologic diseases.

The most valuable redevelopment path may not be rheumatoid arthritis. IRAK4 biology may be more commercially attractive in diseases where innate immune signaling is central and existing therapies have limitations. That strategy would still require new clinical validation.

Key Takeaways

  • PF-06650833 is Pfizer's oral selective IRAK4 inhibitor.
  • The candidate reached Phase 2 clinical development, principally in rheumatoid arthritis.
  • No Phase 3 program, FDA filing, approval, Orange Book listing, or commercial launch has been identified.
  • No Paragraph IV challenge, generic litigation, biosimilar dispute, or settlement agreement has been identified.
  • The base-case market forecast is zero near-term revenue.
  • Commercial value depends on redevelopment, licensing, or repurposing into a better-differentiated inflammatory indication.
  • Patent value cannot be inferred from clinical-stage status alone and requires a family-level review of composition, formulation, manufacturing, and method-of-use claims.
  • Approved JAK inhibitors, biologics, and biosimilars create substantial market-entry pressure in rheumatoid arthritis.
  • PF-06650833 should be valued as a dormant or redevelopment-stage asset, not as a near-launch product.

FAQs

Is PF-06650833 approved by the FDA?

No. PF-06650833 has no identified FDA approval, commercial label, or Orange Book listing.

Is PF-06650833 a JAK inhibitor?

No. PF-06650833 is an IRAK4 inhibitor. Its mechanism targets innate immune signaling rather than the JAK-STAT pathway.

Can a generic company file an ANDA for PF-06650833?

There is no current conventional ANDA market because no approved reference listed drug has been identified for PF-06650833.

Is PF-06650833 being developed for inflammatory bowel disease?

Public development evidence is centered on rheumatoid arthritis. No active late-stage inflammatory bowel disease program has been established for PF-06650833.

Could PF-06650833 still be licensed?

Yes, in principle. A transaction would depend on the remaining patent term, clinical data quality, manufacturing readiness, safety profile, and the sponsor's ability to identify a differentiated indication.

References

  1. ClinicalTrials.gov. (n.d.). Study to evaluate the efficacy and safety of PF-06650833 in participants with rheumatoid arthritis. U.S. National Library of Medicine.

  2. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/

  3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.